Showing 2081-2090 of 2711 results for "".
- Inside Spotlyte: Allergan's Digital Hub to Educate Consumers About Medical Aesthetic Treatmentshttps://modernaesthetics.com/news/inside-spotlyte-allergans-digital-hub-to-educate-consumers-about-medical-aesthetic-treatments/2472038/Allergan has launched Spotlyte, described as an innovative digital hub of curated content that helps consumers discover how medical aesthetic treatments may fit into their routines. Spotlyte
- Candela Acquires Ellipsehttps://modernaesthetics.com/news/candela-acquires-ellipse/2472039/Candela Corporation has acquired Ellipse, a Danish medical device company that manufactures and markets Intense Pulsed Light (IPL) and laser-based platforms for a wide variety of medical and aesthetic skin treatments. Financial terms of the agreement were not disclosed. “The
- Thermi Debuts Arvati Platformhttps://modernaesthetics.com/news/themi-debuts-arvati-platform/2472041/Thermi, an Almirall company, is launching Arvati, a next-generation 510K US Food and Drug Administration-cleared, true temperature-controlled radiofrequen
- Cynosure to Distribute Porter Instrument's Nitrous Oxide and Oxygen System in Aesthetics Markethttps://modernaesthetics.com/news/cynosure-to-distribute-porter-instruments-nitrous-oxide-and-oxygen-system-in-aesthetics-market/2472047/Hologic, Inc.'s Cynosure division has penned a deal with Porter Instrument, a business unit of Parker Hannifin Corporation, for distribution rights in the United States and Canada to Porter Instrument&#
- Evolus Resubmits BLA for DWP-450 Ahead of Schedulehttps://modernaesthetics.com/news/evolus-resubmits-bla-for-dwp-450-ahead-of-schedule/2472049/Evolus has resubmitted its Biologics License Application (BLA) for its lead product candidate, DWP-450 (prabotulinumtoxinA), to the FDA. The resubmission follows the receipt of a Complete Response Letter (“CRL”) from the FDA in May 2018 which necessita
- Bonti's Novel Neurotoxin Shows Promise in Early Study of Scar Reduction After Mohs Surgeryhttps://modernaesthetics.com/news/bontis-novel-neurotoxin-shows-promise-in-early-study-of-scar-reduction-after-mohs-surgery/2472052/Topline results from Bonti’s SHINE-1 Phase 2a clinical trial suggest that its novel neurotoxin is safe and likely effective for scar reduction following Mohs surgery. EB-001, the active ingredient in EB-001A, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique clinical
- With New Applicator, Cryolipolysis is an Option for Male Pseudogynecomastiahttps://modernaesthetics.com/news/withnew-applicator-cryolipolysis-is-an-option-for-male-pseudogynecomastia/2472059/Thanks to a conformable surface applicator, cryolipolysis can be a safe and effective way to treat male pseudogynecomastia, according to a recent
- Power of Two: AMSPA, IALA To Mergehttps://modernaesthetics.com/news/power-of-two-amspa-iala-to-merge/2472062/The American Med Spa Associatio
- RealSelf: Laser & Energy Report Identifies Key Trendshttps://modernaesthetics.com/news/realself-laser-energy-report-identifies-key-trends/2472067/Demand for fat reduction is at an all-time high, and interest in vaginal rejuvenation continues to surge. These are among key findings of the newly release RealSelf US Laser & Energy Report, released this week. First in a ne
- TempSure Vitalia from Cynosure Hits North American Markethttps://modernaesthetics.com/news/tempsure-vitalia-from-cynosure-hits-north-american-market/2472068/Hologic's Cynosure division has launched TempSure™ Vitalia in North America. TempSure Vitalia is an FDA-cleared and Health Canada-approved advanced radiofrequency treatment that delivers therapeutic heat to inter